Tusamitamab Ravtansine in Patients With CEACAM5-positive Advanced Solid Tumors

Tusamitamab Ravtansine in Patients With CEACAM5-positive Advanced Solid Tumors
Conditions:   Breast Cancer Metastatic;   Pancreatic Carcinoma Metastatic
Intervention:   Drug: tusamitamab ravtansine
Sponsor:   Sanofi
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

June 30, 2022Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments